FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Phase 1

Completed

Conditions: Recurrent Adult Acute Myeloid Leukemia
Previously Treated Myelodysplastic Syndrome

Interventions: Drug: Cytarabine
Drug: Decitabine
Drug: Etoposide
Other: Laboratory Biomarker Analysis
Drug: Mitoxantrone Hydrochloride

First Posted Date: 2012-11-20

Last Posted Date: 2019-02-07

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 52

Registration Number: NCT01729845

Locations: 🇺🇸
Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States
🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
EvergreenHealth Medical Center, Kirkland, Washington, United States

Glucosamine and Chondroitin Effects

Not Applicable

Completed

Conditions: Inflammation

Interventions: Dietary Supplement: Glucosamine and Chondroitin
Dietary Supplement: placebo

First Posted Date: 2012-09-11

Last Posted Date: 2014-05-28

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT01682694

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies

Phase 1

Terminated

Conditions: Anaplastic Large Cell Lymphoma
Cutaneous B-cell Non-Hodgkin Lymphoma
Nodal Marginal Zone B-cell Lymphoma
Noncutaneous Extranodal Lymphoma
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Adult Hodgkin Lymphoma
Recurrent Adult T-cell Leukemia/Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Splenic Marginal Zone Lymphoma

Interventions: Biological: indium In 111 anti-CD45 monoclonal antibody BC8
Radiation: yttrium Y 90 anti-CD45 monoclonal antibody BC8
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2012-09-05

Last Posted Date: 2021-04-02

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 2

Registration Number: NCT01678443

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant

Phase 1

Terminated

Conditions: Recurrent Adult Acute Myeloid Leukemia
Recurrent Childhood Acute Myeloid Leukemia
Donor
Hematopoietic Cell Transplant Recipient
Recurrent Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia
Therapy-Related Acute Myeloid Leukemia
HLA-A*0201 Positive Cells Present

Interventions: Biological: Aldesleukin
Other: Laboratory Biomarker Analysis
Drug: Cyclophosphamide
Biological: WT1-Sensitized Allogeneic T-Lymphocytes
Drug: Fludarabine Phosphate

First Posted Date: 2012-07-13

Last Posted Date: 2022-07-14

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 47

Registration Number: NCT01640301

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Phase 1

Withdrawn

Conditions: Hematopoietic/Lymphoid Cancer

Interventions: Drug: brentuximab vedotin
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2012-06-15

Last Posted Date: 2014-04-21

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT01620229

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

FlaxFx, A Research Study of the Effects of Flaxseed Lignans on Colon Health

Not Applicable

Completed

Conditions: Healthy

Interventions: Dietary Supplement: Flaxseed Lignans

First Posted Date: 2012-06-14

Last Posted Date: 2017-09-13

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 66

Registration Number: NCT01619020

Locations: 🇺🇸
FHCRC, Seattle, Washington, United States

Bandage Lenses in Treating Patients With Ocular Graft-Versus-Host Disease

Phase 2

Completed

Conditions: Graft Versus Host Disease
Ophthalmologic Complications

Interventions: Biological: graft versus host disease prophylaxis/therapy
Other: questionnaire administration
Procedure: optical coherence tomography

First Posted Date: 2012-06-11

Last Posted Date: 2017-07-17

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT01616056

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS

Phase 2

Terminated

Conditions: Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Monoblastic Leukemia (M5a)
Adult Erythroleukemia (M6a)
Adult Pure Erythroid Leukemia (M6b)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Refractory Anemia With Excess Blasts
Adult Acute Myelomonocytic Leukemia (M4)
Recurrent Adult Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

Interventions: Drug: decitabine
Drug: idarubicin
Drug: cytarabine

First Posted Date: 2012-05-30

Last Posted Date: 2017-03-31

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 7

Registration Number: NCT01607645

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

INSPIRE: Internet and Social-media Program With Information and Resources for Long-Term Cancer Survivors Who Underwent Stem Cell Transplant

Phase 3

Completed

Conditions: Depression
Myelodysplastic Syndrome
Cancer Survivor
Hematopoietic and Lymphoid Cell Neoplasm

Interventions: Other: Internet-Based Intervention
Other: Medical Chart Review
Other: Questionnaire Administration
Other: Quality-of-Life Assessment

First Posted Date: 2012-05-18

Last Posted Date: 2020-07-31

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 1600

Registration Number: NCT01602211

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

and more 3 locations

Crohn's Allogeneic Transplant Study

Phase 2

Terminated

Conditions: Crohn Disease

Interventions: Procedure: Allogeneic Bone Marrow Transplantation
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Drug: Mycophenolic Acid
Other: Quality-of-Life Assessment
Drug: Tacrolimus
Radiation: Total-Body Irradiation

First Posted Date: 2012-04-04

Last Posted Date: 2020-02-17

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 2

Registration Number: NCT01570348

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy